MAX-001

MAXONA’s initial focus is on advancing an effective and safe treatment for acute and chronic pain.

MAX-001

MAXONA has identified an established European painkiller, as a potential novel analgesic for the U.S. market to help combat the opioid crisis.

Overview

MAX-001 is a patent protected optimized formulation of a powerful oral, fast-acting, non-opioid, non-NSAID analgesic with a novel mechanism of action as a triple neurotransmitter re-uptake inhibitor exerting meaningful effects on norepinephrine, serotonin, and dopamine with the order of strength being N > S > D

MAX-001 Mechanism of Action Image

MAX-001 Mechanism of Action (MOA)

The active molecule in MAX-001 has been used ex-U.S. for decades to treat moderate to severe pain as a single agent or in combination with other analgesics often reducing doses & side-effects of others

  • Currently utilized in 23 countries in which 119 million doses were dispensed worldwide in a recent 12-month period

  • Demonstrated opioid level efficacy without the associated clinical and societal side effects

  • Well characterized safety and efficacy

MAXONA applied its proprietary formulation know how and delivery expertise for MAX-001 to meet four stringent PK criteria

  • Reducing Cmax

  • Extending the duration of effect; while

  • Retaining rapid onset of action; and

  • Maintaining the Area Under the Curve (AUC)

When approved, MAX-001 will bridge the gap for American patients and healthcare providers seeking a safe and efficacious pain relief treatment, without the unwanted side effects of NSAIDs and the addiction risks of opioids.